BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vertex Pharmaceuticals (MA) (VRTX), AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO), Shire plc Get Tax Breaks to Create Jobs


2/23/2012 8:08:15 AM

Boston Business Journal by Julie M. Donnelly, Reporter

Vertex Pharmaceuticals (Nasdaq: VRTX), AVEO Pharmaceuticals (Nasdaq: AVEO) and Shire plc (Nasdaq: SHPGY) are among the companies that will receive substantial tax incentives from the Massachusetts Life Sciences Center (MLSC), in return for creating new jobs. The MLSC, which is tasked with distributing money from the $1 billion Life Sciences Act, has just awarded a total of $21.2 million in tax incentives to 28 life sciences companies, which have promised to create 940 new jobs. If they fail to maintain the jobs for at least five years, the state can take the money back.

Shire, a profitable U.K. company whose rare disease unit is located in Lexington, Mass., has committed to create 100 jobs in return for tax incentives worth $3 million. Cambridge, Mass.-based Vertex, which has had two drugs approved by the FDA in the past year and has recently become profitable, has also promised to create 100 jobs, in return for incentives worth $2.4 million.

Cambridge, Mass.-based AVEO, which could potentially see its first FDA approval for a cancer therapy in the next year, has promised to create 94 jobs in return for incentives worth $2.3 million.

Other companies receiving more than $1 million include Weston, Mass.-based Biogen Idec (Nasdaq: BIIB) which promised to add 75 jobs; Cambridge, Mass.-based Ironwood Pharmaceuticals (Nasdaq: IRWD), which also promised 75 jobs; Cambridge, Mass.-based Momenta Pharmaceuticals (Nasdaq: MNTA) which promised to create 50 jobs, and Raynham, Mass.-based DePuy Othopaedics Inc., which committed to add 50 positions.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES